Novel, Next-Generation HIV-1 Maturation Inhibitor GSK3640254 Demonstrates Dose-Dependent Antiviral Response in Treatment-Naive Patients With HIV Infection

March 6-10, 2021; Virtual
Phase IIa study demonstrates that novel maturation inhibitor exhibits dose-response antiviral activity, in vivo concentrations above clinical efficacy targets, and good tolerability.
Format: Microsoft PowerPoint (.ppt)
File Size: 223 KB
Released: March 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options’ (CCO) commentary from a person with HIV on what it was like living through the COVID-19 pandemic as a long-term HIV survivor

person default Frank Primavera Released: June 9, 2021

Slides from CCO: Switching ART in HIV: 3-drug therapy, oral 2-drug options, long-acting injectable 2-drug regimens, single tablet regimens (STRs)

Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: June 7, 2021

CCO slides from Drs. Joseph J. Eron, Jr, and Darcy Wooten on the implications of emerging ART safety and tolerability data when managing HIV treatment

Joseph J. Eron, Jr., MD Darcy Wooten, MD Released: May 11, 2021

Clinical Care Options (CCO) video of faculty discussion on the implications of emerging ART safety and tolerability data when managing HIV treatment

Joseph J. Eron, Jr., MD Darcy Wooten, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 11, 2021 Expired: May 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue